SHENGDA BIO-PHARM(SH:603079) 智通财经网·2026-01-22 07:50Core Viewpoint - The company, Shengda Bio (603079.SH), expects a significant increase in net profit for the year 2025, projecting a growth of 69.93% to 120.90% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the owners of the parent company for 2025 is projected to be between 50 million to 65 million yuan [1] - The estimated net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be between 43 million to 58 million yuan, reflecting a growth of 91.42% to 158.19% [1] Operational Strategy - The company has improved operational efficiency and cost structure through continuous fine management and technological upgrades [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts to seize market opportunities, enhancing overall profitability [1]